Results 31 to 40 of about 774,384 (405)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials [PDF]

, 2013
Rationale Clinical trial design in interstitial lung diseases (ILDs) has been hampered by lack of consensus on appropriate outcome measures for reliably assessing treatment response.
Antoniou, K, Baughman, RP, Brown, KK, Castelino, FV, Christmann, RB, Christopher-Stine, L, Collard, HR, Cottin, V, Danoff, S, Dellaripa, PF, Denton, CP, Distler, O, Fischer, A, Flaherty, KR, Frankel, S, Highland, KB, Hummers, L, Huscher, D, Khanna, D, Kim, DS, Kowal-Bielecka, OM, LeSage, D, Lynch, DA, Matteson, EL, Merkel, PA, Miller, FW, Mittoo, S, Oddis, CV, Phillips, K, Pittrow, D, Proudman, SM, Richeldi, L, Ryu, JH, Saketkoo, LA, Sandorfi, N, Sarver, C, Seibold, JR, Shah, AA, Strand, V, Swigris, J, Wells, AU   +40 more
core   +1 more source

Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997-2008 [PDF]

, 2016
Introduction: International guidelines and new targeted therapies for idiopathic pulmonary fibrosis have increased the need for accurate diagnosis of interstitial lung disease, which may lead to more surgical lung biopsies.
Fogarty, Andrew W., Hubbard, Richard B., Hutchinson, John P., McKeever, Tricia M., Navaratnam, Vidya   +4 more
core   +2 more sources

Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome

ERJ Open Research, 2021
Introduction Idiopathic pulmonary fibrosis (IPF) prognosis is heterogeneous despite antifibrotic treatment. Cluster analysis has proven to be a useful tool in identifying interstitial lung disease phenotypes, which has yet to be performed in IPF. The aim
Jaume Bordas-Martínez, Ricard Gavaldà, Jessica G. Shull, Vanesa Vicens-Zygmunt, Lurdes Planas-Cerezales, Guadalupe Bermudo-Peloche, Salud Santos, Neus Salord, Carmen Monasterio, Maria Molina-Molina, Guillermo Suarez-Cuartin   +10 more
doaj   +1 more source

Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry

European Respiratory Journal, 2021
Pulmonary hypertension (PH) is a common complication of many chronic lung diseases, especially COPD and interstitial lung disease (ILD) [1]. In these conditions, the development of PH is associated with an aggravation of symptoms and an increase in ...
K. Olsson, M. Hoeper, C. Pausch, E. Grünig, D. Huscher, D. Pittrow, S. Rosenkranz, H. Gall   +7 more
semanticscholar   +1 more source

Personalised medicine in interstitial lung diseases

European Respiratory Review, 2018
Interstitial lung diseases in general, and idiopathic pulmonary fibrosis in particular, are complex disorders with multiple pathogenetic pathways, various disease behaviour profiles and different responses to treatment, all facets that make personalised ...
Maria A. Kokosi, George A. Margaritopoulos, Athol U. Wells   +2 more
doaj   +1 more source

MRI of the lung (3/3)-current applications and future perspectives [PDF]

, 2011
BACKGROUND: MRI of the lung is recommended in a number of clinical indications. Having a non-radiation alternative is particularly attractive in children and young subjects, or pregnant women.
A Hebestreit, A Kluge, A Kluge, A Kluge, AA Bankier, AC Henderson, AS Brody, BJ Pichler, BJ Pichler, C Fink, C Hintze, C Hintze, C Rieger, CA Yi, CA Yi, CP Heussel, DM Mannino, F Molinari, F Risse, F Santamaria, G Antoch, G Antoch, G Bauman, G Bauman, G Lutterbey, G Lutterbey, G Sergiacomi, H Hatabu, H Zaidi, HF Wehrl, HK Song, HK Song, IL Theissen, J Biederer, J Biederer, J Biederer, J Biederer, J Biederer, J Biederer, J Biederer, J Ley-Zaporozhan, J Ley-Zaporozhan, JC Hogg, K Cederlund, K Sandek, K Suga, K Suga, LP Qi, M Bhalla, M Decramer, M Eichinger, M Gaeta, M Oudkerk, M Puderbach, M Puderbach, M Puderbach, M Puderbach, M Stern, M Wagner, MD Cohen, ND Abolmaali, NJ Morrison, NL Müller, O Ratib, PA Jong de, PA Jong de, PD Stein, PD Stein, R Eibel, R Failo, RE Jacob, RG McFadden, RJ Theilmann, RL Gibson, S Akata, S Montella, S Pauls, SK Alford, T Amundsen, T Iwasawa, T Iwasawa, T Iwasawa, T Mori, T Rupprecht, TA Kuder, TH Helbich, US Euler, V Peltola, W Hirsch, W Lin, Y Berthezène, Y Ohba, Y Ohno, Y Ohno, Y Ohno, Y Ohno, Y Shao   +96 more
core   +1 more source

Genetic and environmental factors in interstitial lung diseases: current and future perspectives on early diagnosis of high-risk cohorts

Frontiers in Medicine, 2023
Within the wide scope of interstitial lung diseases (ILDs), familial pulmonary fibrosis (FPF) is being increasingly recognized as a specific entity, with earlier onset, faster progression, and suboptimal responses to immunosuppression.
Stefan Cristian Stanel, Stefan Cristian Stanel, Jack Callum, Pilar Rivera-Ortega   +3 more
doaj   +1 more source

The role of nailfold capillaroscopy in interstitial lung diseases - Can it differentiate idiopathic cases from collagen tissue disease associated interstitial lung diseases? [PDF]

, 2015
Introduction: Nailfold capillaroscopy (NFC) is a non-invasive diagnostic test that is mostly used for early diagnosis of collagen tissue diseases (CTDs). We aimed to evaluate whether NFC findings could be a clue for discriminating idiopathic interstitial
Altınışık, Göksel, Balkarli, A., Çakmakçi Karadoğan, D., Çobankara, Veli, Önal, Özgür   +4 more
core   +1 more source

Predictors of progression in systemic sclerosis patients with interstitial lung disease

European Respiratory Journal, 2020
Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in SSc.
O. Distler, S. Assassi, V. Cottin, M. Cutolo, S. Danoff, C. Denton, J. Distler, A. Hoffmann-Vold, S. Johnson, U. Müller Ladner, V. Smith, E. Volkmann, T. Maher   +12 more
semanticscholar   +1 more source

Genetic Interstitial Lung Disease [PDF]

Clinics in Chest Medicine, 2012
The interstitial lung diseases (ILDs), or diffuse parenchymal lung diseases, are a heterogeneous collection of more than 100 different pulmonary disorders that affect the tissue and spaces surrounding the alveoli. Patients affected by ILD usually present with shortness of breath or cough; for many, there is evidence of pulmonary restriction, decreased ...
Megan Stuebner, Devine, Christine Kim, Garcia   +1 more
openaire   +2 more sources